Shares of Integra LifeSciences Holdings Corp. (NASDAQ:IART) dropped 1.2% on Monday . The stock traded as low as $80.43 and last traded at $80.51, with a volume of 193,782 shares changing hands. The stock had previously closed at $81.45.

IART has been the subject of several recent analyst reports. TheStreet upgraded Integra LifeSciences Holdings Corp. from a “hold” rating to a “buy” rating in a research note on Friday, April 1st. Zacks Investment Research upgraded Integra LifeSciences Holdings Corp. from a “hold” rating to a “buy” rating and set a $79.00 target price for the company in a research note on Monday, May 2nd. Jefferies Group restated a “buy” rating on shares of Integra LifeSciences Holdings Corp. in a research note on Thursday, April 28th. Oppenheimer Holdings Inc. restated a “buy” rating on shares of Integra LifeSciences Holdings Corp. in a research note on Thursday, April 28th. Finally, Barclays PLC raised their target price on Integra LifeSciences Holdings Corp. from $74.00 to $77.00 and gave the company an “equal weight” rating in a research note on Thursday, June 2nd. Two analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $79.00.

The company’s 50-day moving average price is $76.65 and its 200 day moving average price is $67.84. The company’s market capitalization is $3.00 billion.

Integra LifeSciences Holdings Corp. (NASDAQ:IART) last posted its earnings results on Wednesday, April 27th. The company reported $0.74 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.73 by $0.01. The firm earned $236.80 million during the quarter, compared to analyst estimates of $230.66 million. During the same quarter last year, the business posted $0.76 earnings per share. The company’s revenue for the quarter was up 1.3% on a year-over-year basis. Analysts predict that Integra LifeSciences Holdings Corp. will post $3.44 EPS for the current year.

In other news, VP Joseph Vinhais sold 972 shares of the stock in a transaction on Monday, May 9th. The shares were sold at an average price of $73.36, for a total transaction of $71,305.92. Following the completion of the sale, the vice president now owns 4,311 shares of the company’s stock, valued at $316,254.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Glenn Coleman sold 3,563 shares of the stock in a transaction on Wednesday, May 4th. The stock was sold at an average price of $70.62, for a total transaction of $251,619.06. Following the sale, the chief financial officer now directly owns 12,263 shares of the company’s stock, valued at approximately $866,013.06. The disclosure for this sale can be found here.

Other large investors recently modified their holdings of the company. New York State Common Retirement Fund increased its stake in shares of Integra LifeSciences Holdings Corp. by 3.9% in the fourth quarter. New York State Common Retirement Fund now owns 26,400 shares of the company’s stock valued at $1,789,000 after buying an additional 1,000 shares in the last quarter. Comerica Bank increased its stake in shares of Integra LifeSciences Holdings Corp. by 1.4% in the fourth quarter. Comerica Bank now owns 29,922 shares of the company’s stock valued at $1,965,000 after buying an additional 401 shares in the last quarter. GSA Capital Partners LLP increased its stake in shares of Integra LifeSciences Holdings Corp. by 160.4% in the fourth quarter. GSA Capital Partners LLP now owns 34,122 shares of the company’s stock valued at $2,313,000 after buying an additional 21,020 shares in the last quarter. IronBridge Capital Management LP bought a new stake in shares of Integra LifeSciences Holdings Corp. during the fourth quarter valued at about $2,992,000. Finally, Rhumbline Advisers increased its stake in shares of Integra LifeSciences Holdings Corp. by 6.6% in the fourth quarter. Rhumbline Advisers now owns 45,298 shares of the company’s stock valued at $3,070,000 after buying an additional 2,820 shares in the last quarter.

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing and marketing of surgical implants and medical instruments. Its products are used in neurosurgery, extremity reconstruction, orthopedics and general surgery. Its segments include Specialty Surgical Solutions, which offers products, including specialty surgical instrumentation for a range of specialties.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.